15.06.2018 PR, реклама, маркетинг

Nonalcoholic Steatohepatitis Therapeutics Market Overview, Challenges, Opportunities, Trends and Market Analysis by 2023

The global nonalcoholic steatohepatitis (NASH) therapeutics market is expected to witness significant growth due to current unmet medical need of NASH, scarcity of the permanent treatment of the disease, increasing prevalence of obesity, and high demand for safe and effective medication.

Request to Get the Sample Report@ https://www.psmarketresearch.com/market-analysis/nash-therapeutics-market/report-sample

The regulatory bodies are supporting the NASH market by providing designations and funding for speeding up the drug development process. In March 2015, obeticholic acid, an investigational Phase III clinical trial drug candidate of Intercept Pharmaceuticals Inc., received breakthrough therapy designation from the U.S. Food and Drug Administration for the treatment of patients with NASH.

Full Explore Report@ https://www.psmarketresearch.com/market-analysis/nash-therapeutics-market

A large number of pharmaceutical companies are investing huge capital for the development of NASH therapeutics. However, certain factors such as unknown etiology, complex pathophysiology, and high treatment cost of NASH are expected to hamper the growth of the global market during the forecast period.

Geographically, North America is expected to be the largest market for NASH therapeutics owing to the large number of research and development activities, high healthcare expenditure and high incidence of obesity. The U.S. contributed largest revenue to the North American market and it is expected to remain the largest market globally, during the forecast period.

Make Enquiry Before Buying the Report@ https://www.psmarketresearch.com/send-enquiry?enquiry-url=nash-therapeutics-market


Some of the key players operating in the global NASH therapeutics market are Genfit SA, Gilead Sciences, Inc., Novo Nordisk A/S, Intercept Pharmaceuticals, Inc., Enzo Biochem, Inc., Raptor Pharmaceutical Corp., Conatus Pharmaceuticals Inc., Zydus Cadila Healthcare Limited., Novartis AG, and Shire plc.